Hurwitz HI - Search Results

1

Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance).

Nixon AB, Pang H, Starr MD, Friedman PN, Bertagnolli MM, Kindler HL, Goldberg RM, Venook AP, Hurwitz HI; Alliance for Clinical Trials In Oncology. Nixon AB, et al. Among authors: hurwitz hi. Clin Cancer Res. 2013 Dec 15;19(24):6957-66. doi: 10.1158/1078-0432.CCR-13-0926. Epub 2013 Oct 4. Clin Cancer Res. 2013. PMID: 24097873 Free PMC article.

2

Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor.

Lockhart AC, Braun RD, Yu D, Ross JR, Dewhirst MW, Humphrey JS, Thompson S, Williams KM, Klitzman B, Yuan F, Grichnik JM, Proia AD, Conway DA, Hurwitz HI. Lockhart AC, et al. Among authors: hurwitz hi. Clin Cancer Res. 2003 Feb;9(2):586-93. Clin Cancer Res. 2003. PMID: 12576422 Clinical Trial.

3

Targeted therapy of colorectal cancer: clinical experience with bevacizumab.

Fernando NH, Hurwitz HI. Fernando NH, et al. Among authors: hurwitz hi. Oncologist. 2004;9 Suppl 1:11-8. doi: 10.1634/theoncologist.9-suppl_1-11. Oncologist. 2004. PMID: 15178811 Free article. Review.

4

Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma.

Blackwell K, Hurwitz H, Liebérman G, Novotny W, Snyder S, Dewhirst M, Greenberg C. Blackwell K, et al. Cancer. 2004 Jul 1;101(1):77-82. doi: 10.1002/cncr.20336. Cancer. 2004. PMID: 15221991 Free article. Clinical Trial.

5

Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer.

Hurwitz H. Hurwitz H. Clin Colorectal Cancer. 2004 Oct;4 Suppl 2:S62-8. doi: 10.3816/ccc.2004.s.010. Clin Colorectal Cancer. 2004. PMID: 15479481 Review.

6

Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer.

White RR, Xie HB, Gottfried MR, Czito BG, Hurwitz HI, Morse MA, Blobe GC, Paulson EK, Baillie J, Branch MS, Jowell PS, Clary BM, Pappas TN, Tyler DS. White RR, et al. Among authors: hurwitz hi. Ann Surg Oncol. 2005 Mar;12(3):214-21. doi: 10.1245/ASO.2005.03.105. Epub 2005 Mar 3. Ann Surg Oncol. 2005. PMID: 15827813

7

Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer.

Jubb AM, Hurwitz HI, Bai W, Holmgren EB, Tobin P, Guerrero AS, Kabbinavar F, Holden SN, Novotny WF, Frantz GD, Hillan KJ, Koeppen H. Jubb AM, et al. Among authors: hurwitz hi. J Clin Oncol. 2006 Jan 10;24(2):217-27. doi: 10.1200/JCO.2005.01.5388. Epub 2005 Dec 19. J Clin Oncol. 2006. PMID: 16365183 Clinical Trial.

8

Angiogenesis inhibition in the treatment of colorectal cancer Part 3 of a 3-part series: targeting VEGF--current and future research directions.

Goldberg RM, Hurwitz HI, Fuchs CS. Goldberg RM, et al. Among authors: hurwitz hi. Clin Adv Hematol Oncol. 2005 Dec;3(12):1-10; quiz 11. Clin Adv Hematol Oncol. 2005. PMID: 16555433

9

Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case report.

Hurwitz HI, Honeycutt W, Haley S, Favaro J. Hurwitz HI, et al. Clin Colorectal Cancer. 2006 May;6(1):66-9. doi: 10.3816/CCC.2006.n.023. Clin Colorectal Cancer. 2006. PMID: 16796794

10

The role of targeted therapy in the treatment of colorectal cancer.

Goldberg RM, Hurwitz HI, Fuchs CS. Goldberg RM, et al. Among authors: hurwitz hi. Clin Adv Hematol Oncol. 2006 Aug;4(8 Suppl 17):1-10; quiz 11-2. Clin Adv Hematol Oncol. 2006. PMID: 17139241 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

214 results

Search Page

Filters